GLP-1 Receptor Agonism Across Disease Domains: Positive Cardiometabolic Outcomes Coexist with Negative Symptomatic Alzheimer Disease Readouts

GLP-1 receptor agonists have produced positive cardiovascular and weight-loss outcomes while failing primary endpoints in symptomatic Alzheimer disease and showing early signal in Parkinson disease; the class is not a single-disease story.

Type

evidence-claim

Domain

h06_deregulated_nutrient_sensing

Grade

A

License

CC BY-NC 4.0

card_id

L-016

hallmarks

h06_deregulated_nutrient_sensing,h11_chronic_inflammation

cluster

clinical_translation

primary_disease_area

alzheimers,parkinsons,longevity_general

evidence_tier

A

evidence_anchor_count

7

intake_round

R23

intake_date

2026-05-26

related_experts

related_biomarkers

related_interventions

related_trials

NCT03574597,NCT04777396,NCT04777409,NCT03439943

collection_pages

/research/interventions/glp1-agonists,/research/cases/cross-disease-pharmacology

LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source

Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.